Interaction of the SARS-Coronavirus with the interferon system
Interaction of the SARS-Coronavirus with the interferon system
批准号:
5437828
负责人:
Professor Dr. Friedemann Weber
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2004
资助国家:
德国
项目状态:
已结题
起止时间:
2003-12-31 至 2007-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Alpha/beta interferons (IFNs) are potent cytokines with antiviral activity. They are induced by virus infection and trigger the expression of antiviral proteins. To counteract this, viruses have evolved so-called IFN antagonists, which interfere with either IFN induction, IFN signaling, or the action of IFN effector proteins. We found that SARS-CoV is strongly inhibited by IFN-beta and by a novel IFN, IFN-omega. IFN-alpha, by contrast, was less effective. Furthermore, it was found that cells infected with SARS-CoV are unable to synthesize IFN, indicating that SARS-CoV encodes at least one factor with IFN-antagonistic activity. The proposed studies of the German team will be aimed at (i) identifying the host-encoded IFN-induced proteins which are responsible for the antiviral effect against SARS-CoV, (ii) screening the SARS-CoV genome for proteins with anti-IFN activity, and (iii) characterizing the IFN-antagonistic mechanism. The Chinese team will investigate virus isolates from Chinese patients for potential differences in the anti-IFN genes. The activity of those IFN-antagonistic genes of Chinese virus isolates will be compared to each other and to cell culture adapted virus isolates. Furthermore, levels of different IFNs will be measured in patients' material and tested whether there is a correlation with disease progression and with certain IFN antagonist sequences. IFN-omega is licensed by the Chinese FDA for prevention of SARS by intranasal spray application. Comparative studies concerning the antiviral effects and the differently induced IFN effectors of IFN-omega, -beta, or -alpha in will help to clarify which antiviral protein most potently inhibits SARS-CoV. These studies may lead to the identification of virulence mechanisms and host defense factors which influence the outcome of infection with SARS-CoV. Long-term benefits of those studies could be the improvement of antiviral therapy and the rational design of SARS-CoV vaccines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Degradation of the antiviral interferon-effector PKR by the virulence factor NSs of Rift Valley fever virus
-
批准号:19350534
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2005
-
负责人:Professor Dr. Friedemann Weber
-
依托单位:
Funktion des Nichtstrukturproteins NSs der Bunyaviren als Virulenzfaktor
-
批准号:5286114
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2000
-
负责人:Professor Dr. Friedemann Weber
-
依托单位:
国内基金
海外基金
登录
查看更多内容
SUMO化介导泛素化修饰类型调控N蛋白水平及SARS-CoV-2复制的机制研究
-
批准号:JCZRQN202500077
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
SARS-CoV-2 VLP调控肿瘤微环境影响三阴性乳腺癌发生发展的机制
研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
基于Smad3调控铁死亡和炎症反应探讨SARS-CoV-2N蛋白诱发糖尿病基础上急性肾损伤的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:梁莉莹
-
依托单位:
SARS-TRNAU1AP调控小胶质细胞tRNA稳定性在生发基质-脑室出血后神经炎症的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:李鹏
-
依托单位:
靶向SARS-CoV-2 S1蛋白中药多糖活性化合物的筛选及构效关系研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2024
-
负责人:李美霞
-
依托单位:
cGAS-STING 通路在 SARS-CoV-2 感染致急性肺损
伤的机制研究
-
批准号:2024JJ2038
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:晏锡泉
-
依托单位:
SARS相关冠状病毒刺突蛋白不同功能区的协同作用及其机制研究
-
批准号:32300141
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:郭华
-
依托单位:
SARS-CoV-2 N蛋白激活SCAP-SREBP2/Notch1信号通路促进动脉粥样硬化进展及其机制研究
-
批准号:82360101
-
项目类别:地区科学基金项目
-
资助金额:32万元
-
批准年份:2023
-
负责人:刘米华
-
依托单位:
SARS-CoV-2及其变异株B/T细胞表位的鉴定及表位疫苗的设计和免疫保护性研究
-
批准号:82302065
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:雷清
-
依托单位:
腺苷酸转位酶在SARS-CoV-2感染中的作用及分子机制研究
-
批准号:32302955
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:李乐天
-
依托单位: